Gilead announced the intention to release more than 2 million courses of the drug ramdevpir, which is regarded as an effective means of therapy for coronavirus infection. The company also plans to conduct clinical studies with inhaled forms of the drug, writes Reuters.
Antiretroviral ramdevpir was the first drug that demonstrated in clinical studies its effectiveness in the treatment of coronavirus infection. In some countries (including the US) have allowed its use in the fight against the pandemic COVID-19.
Currently, medicine is available in form for intravenous injection, however, in August 2020 Gilead intends to begin clinical trials more easy to use form LS – inhalation. The company explained that the delivery of the drug with a nebulizer will simplify its use in ambulatory patients.